Jump to top menu Jump to main menu Jump to content
Profilepicture of Britt Dhaenens
Researcher

B.A.E. (Britt) Dhaenens

PhD-student Neurofibromatosis

  • Department
  • General Pediatrics
  • Focus area
  • Patient-reported outcome measures, Quality of Life, clinical trials in Neurofibromatosis.
Contact  

About B.A.E. (Britt) Dhaenens

Introduction

Hello everyone! My name is Britt Dhaenens and I work as a PhD-student at the Erasmus MC Sophia Children's Hospital. Before my PhD, I studied Medicine at the Erasmus MC, from which I graduated in 2019. I aim to be a children's Neurologist after my PhD. 

My PhD revolves around the hereditary condition Neurofibromatosis (NF). We aim to set up a big international trial for this condition. In addition, I focus on the development of patient-reported outcome measures for NF. I also work as a study coordinator for the SPRINKLE study. This study investigates the effectiveness of a certain medicine of plexiform neurofibroma in children with NF1.

Education and career

2012 - 2019: Medical school at Erasmus MC.

2020 - 2022: Second master’s in health sciences at the Dutch Institute for Health Sciences (NIHES).

Publications

Identifying challenges in neurofibromatosis: a modified Delphi procedure. Britt A E Dhaenens, Rosalie E Ferner, Annette Bakker, Marco Nievo, D Gareth Evans, Pierre Wolkenstein, Cornelia Potratz, Scott R Plotkin, Guenter Heimann, Eric Legius, Rianne Oostenbrink. Eur J Hum Genet. 2021 Nov;29(11):1625-1633.

Lessons learned from drug trials in neurofibromatosis: A systematic review. Britt A E Dhaenens, Rosalie E Ferner, D Gareth Evans, Guenter Heimann, Cornelia Potratz, Edwin van de Ketterij, Angela M Kaindl, Geesje Hissink, Charlotte Carton, Annette Bakker, Marco Nievo, Eric Legius, Rianne Oostenbrink. Eur J Med Genet. 2021 Sep;64(9):104281.

Teaching activities

Supervision of multiple theses of Medicine master students.

Scholarships, grants, and awards

Received €40.000 from the Neurofibromatosis patient organization (NFVN) for the research of brain tumours in patients with Neurofibromatosis Type 1.